Breast Cancer HER2 (ERBB2) Status by Next-Generation Sequencing Compared to Traditional Methods

被引：0
|
作者：
Russell, Meaghan K. [1 ]
Pantazi, Angeliki [1 ]
Lyle, Stephen [2 ]
Tse, Julie Y. [3 ]
机构：
[1] KEW Inc, Lethbridge, AB, Canada
[2] Univ Massachusetts, Worcester, MA 01605 USA
[3] KEW Inc, Tufts Med Ctr, Boston, MA USA
来源：
LABORATORY INVESTIGATION | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
291
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [31] Future options in the treatment of ErbB2 (HER2)-positive breast cancer
    Fumoleau, Pierre
    EJC SUPPLEMENTS, 2008, 6 (05): : 25 - 31
  • [32] Tucatinib HER2 (ErbB2) inhibitor Treatment of breast and colorectal cancer
    Patil, T.
    Shagisultanova, E.
    Borges, V. F.
    DRUGS OF THE FUTURE, 2019, 44 (01) : 11 - 19
  • [33] COMPLETE - Study the ErbB2 (HER2) - positive Breast cancer.
    Arnheim, Katharina
    Aktas, Bahriye
    ONKOLOGIE, 2010, 33 (04):
  • [34] ErbB2 (HER2)-positives MammakarzinomResistenzmechanismenErbB2 (HER2) positive breast cancer Mechanisms of resistance
    K. Kast
    W. Distler
    Der Gynäkologe, 2010, 43 (7): : 574 - 578
  • [35] Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Status in Breast Cancer: A Focus on Group 4 Using the 2018 ASCO/CAP HER2 Testing Guideline
    Hoda, Raza
    Bowman, Anita
    Zehir, Ahmet
    Brogi, Edi
    Ladanyi, Marc
    Arcila, Maria
    Wen, Hannah
    Ross, Dara
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 175 - 177
  • [36] Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Status in Breast Cancer: A Focus on Group 4 Using the 2018 ASCO/CAP HER2 Testing Guideline
    Hoda, Raza
    Bowman, Anita
    Zehir, Ahmet
    Brogi, Edi
    Ladanyi, Marc
    Arcila, Maria
    Wen, Hannah
    Ross, Dara
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 175 - 177
  • [37] ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
    David F. Stern
    Journal of Mammary Gland Biology and Neoplasia, 2008, 13
  • [38] Next-generation sequencing based detection of HER2 copy number predicts pathological response to neoadjuvant therapy in HER2 positive breast cancer
    Dai, Hao
    Jiao, Dechuang
    Guo, Xuhui
    Qiao, Jianghua
    Li, Anfang
    Lu, Zhenduo
    Chen, Xiuchun
    Wang, Chengzheng
    Yan, Min
    Liu, Zhenzhen
    CANCER RESEARCH, 2024, 84 (06)
  • [39] ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
    Stern, David F.
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2008, 13 (02) : 215 - 223
  • [40] Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer Close Enough?
    Burstein, Harold J.
    Schrag, Deborah
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (01): : 30 - 32
12345